CAMBRIDGE, Mass., December 9, 2021 / PRNewswire / – Totus Medicines, a drug discovery company using breakthrough chemical biology to make the entire human genome medicinable, today unveiled its breakthrough drug program targeting PI3Kα, the most commonly mutated cancer oncogene. The company also announced a $ 40 million Series A round of funding led by DCVC Bio investors and Northpond Ventures and backed by Camford Capital with seed funding of Social impact capital. The Series A funding will be used to expand and evolve Totus Medicines’ proprietary drug discovery platform and advance the company’s core program in the clinic.
Totus Medicines’ TOS-358 drug program targets the PI3Kα mutation, which affects more than 500,000 people in the United States each year and causes a significant percentage of cancers of the breast, colon, lung, bladder, lung stomach and others. The pharmaceutical industry has spent decades and billions of dollars trying to target PI3Kα, and current inhibitors have only moderate success in less than 10% of patients with PI3Kα mutant cancers.
In just 18 months, Totus used its proprietary drug discovery platform to develop TOS-358, which shows high preclinical efficacy on PI3Kα-mutant tumor types where current PI3Kα inhibitors show little or no efficacy. . In patient-derived mouse xenograft models, TOS-358 induces tumor regressions in breast, colon, lungs, stomach and other models, while current inhibitors show mild effects. Totus Medicines will begin clinical trials of the TOS-358 drug program in the second half of 2022.
“Our drug discovery platform is capable of creating treatments for previously incurable diseases,” said Neil dhawan, Ph.D., co-founder and CEO of Totus Medicines. “We are drugging non-drug targets at scale, bringing us closer to a world where every doctor and patient can expect effective treatments for the most devastating diseases. The TOS-358 drug program is a crowning achievement in this process. mission, and we look forward to advancing the program – and many others – in the clinic. “
Totus Medicines’ platform uses proprietary molecular markers that track drug binding in individual cells to screen billions of drug molecules across thousands of genes in parallel. By combining this approach with revolutionary machine learning techniques, the company has developed the next generation of cell analysis. By constantly learning and adapting, the Totus platform is more efficient, less expensive, and thousands of times faster than traditional drug discovery methods, enabling rapid translation of therapies for patients. Totus aims to screen two billion compounds across the human genome over the next two years to unlock precise and effective drugs on hundreds of high-value drug targets.
“The Series A funding will allow us to refine and expand the Totus platform to find new treatments for previously incurable diseases, faster and with more success than has ever been possible,” said Jason pontin, partner of DCVC, member of the board of directors and co-founder of Totus Medicines. “The promise of Totus Medicines is that doctors can deliver life-changing drugs to patients who would otherwise have little hope.”
About Totus Medicines
Founded in 2019, Totus Medicines uses revolutionary chemical biology to create life-changing therapies to treat previously incurable diseases across the human genome. Totus is based at Cambridge, Massachusetts.
For more information, please visit totusmedicines.com and follow Totus on LinkedIn and Twitter.
SOURCE Totus Medicines